ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Pre-Market Trading 03-26 06:50:30 EDT

20.22

-0.10

-0.49%

High20.70	Low19.93	Vol2.40M
Open20.24	D1 Closing20.32	Amplitude3.81%
Mkt Cap4.80B	Tradable Cap4.71B	Total Shares237.62M
T/O48.56M	T/O Rate1.03%	Tradable Shares232.89M
P/B13.77	ROE81.65%	EPS0.81
52wk High23.64	52wk Low5.90	P/E24.96
Dividend0.00	Div.Yield0.00	ROA21.24%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":20.22,"timestamp":1742932800000,"preClose":20.32,"halted":0,"volume":2402626,"delay":0,"floatShares":232889244,"shares":237615100,"eps":0.809999,"marketStatus":"Pre-Market Trading","change":-0.1,"latestTime":"03-26 06:50:29 EDT","open":20.24,"high":20.7,"low":19.925,"amount":48559084.860588,"amplitude":0.03814,"askPrice":20.89,"askSize":30,"bidPrice":19.31,"bidSize":30,"shortable":3,"etf":0,"ttmEps":0.809999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742995800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":20.22,"postHourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":20.22,"latestTime":"19:34 EDT","volume":135063,"amount":2731893.717,"timestamp":1742945677614},"volumeRatio":0.509329191928341,"impliedVol":0.6491,"impliedVolPercentile":0.5783},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"2521268068","title":"Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2521268068","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521268068?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:43","pubTimestamp":1742589797,"startTime":"0","endTime":"0","summary":"Adma Biologics  has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this infectious disease drug developer have returned +22.2% over the past month versus the Zacks S&P 500 composite's -7.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.For the current quarter, Adma Biologics is expected to post earnings of $0.16 per share, indicating a change of +100% from the year-ago quarter. The Zacks Consensus Estimate has changed +6.7% over the last 30 days.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-beyond-why-adma-biologics-204317169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4585","BK4588","BK4178","BK4139"],"gpt_icon":0},{"id":"2521842187","title":"ADMA Biologics: Strong Growth Prospects and Stability Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2521842187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521842187?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 14:56","pubTimestamp":1742540185,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on ADMA stock, giving a Buy rating on March 3. Anthony Petrone has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adma-biologics-strong-growth-prospects-and-stability-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adma-biologics-strong-growth-prospects-and-stability-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADMA"],"gpt_icon":0},{"id":"2520146329","title":"Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520146329","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520146329?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:28","pubTimestamp":1742477280,"startTime":"0","endTime":"0","summary":"Adma Biologics  shares soared 10.2% in the last trading session to close at $20.61. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks.The sudden soaring of the stock price can be attributed to a positive investor mindset regarding the continued sales growth of ADMA Biologics’ three FDA-approved products, namely – Bivigam , Asceniv  and Nabi-HB . In 2024, the company recorded total revenues of $426.5 million entirely from product sales, representing an increase of 65% on a year-over-year basis.This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-over-year change of +100%. Revenues are expected to be $119.1 million, up 45.5% from the year-ago quarter.ADMA Biologics Inc  : Free Stock Analysis Report. WAVE Life Sciences Ltd.  : Free Stock Analysis Report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-surges-10-132800509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4007","WVE","BK4139"],"gpt_icon":1},{"id":"2520459481","title":"Why ADMA Biologics Inc. (ADMA) Went Up On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520459481","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520459481?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 09:02","pubTimestamp":1742432549,"startTime":"0","endTime":"0","summary":"The stock market regained momentum on Wednesday, with all main indices ending in the green, as investors cheered the Federal Reserve’s decision to keep interest rates unchanged.The tech-heavy Nasdaq led the gains, rallying 1.41 percent, followed by the S&P 500 with a 1.08 percent gain, and the Dow Jones, by 0.92 percent.Optimism spilled over into companies, with 10 particularly leading the charge. In this article, we have identified Wednesday’s 10 best performers and detailed the reasons behind their gains.To come up with the list, we considered only the companies with a $2-billion market capitalization and $5 million in trading volume.An independent distributor in their pharmacy with a range of biopharmaceutical products on display.ADMA Biologics extended its winning streak for a fourth straight day on Wednesday, adding 10.16 percent to finish at $20.61 apiece in line with the overall market rally, further supported by a bullish outlook and impressive earnings performance last year.Di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-adma-biologics-inc-adma-010229501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","QID","NVIW.SI","TSYW.SI","MNQmain","ADMA","PSQ","SQQQ","USAW.SI","USJW.SI","BK4139","TQQQ","NQmain",".IXIC"],"gpt_icon":1},{"id":"2520333039","title":"Centene's Meridian Unit Secures a D-SNP Contract in Illinois","url":"https://stock-news.laohu8.com/highlight/detail?id=2520333039","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520333039?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 00:32","pubTimestamp":1742315520,"startTime":"0","endTime":"0","summary":"Centene Corporation CNC recently unveiled that its Illinois subsidiary, Meridian Health Plan of Illinois, Inc., has been chosen by the Illinois Department of Healthcare and Family Services  to continue providing enhanced managed care services to 77,000 dually eligible residents via a Fully Integrated Dual Eligible Special Needs Plan .This program will provide comprehensive care and support across the state for individuals who qualify for both Medicare and Medicaid, including those enrolled in Managed Long-Term Services and Supports , under a unified managed care organization.The new D-SNP contract is likely to take effect on Jan. 1, 2026, and will run until Dec. 31, 2029. The state retains the option to extend the contract in intervals ranging from six months to five and a half years, allowing for a maximum duration of up to 10 years. Under the new contract, Meridian will take a holistic approach to member care by eliminating healthcare barriers and enhancing behavioral health services","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centenes-meridian-unit-secures-d-163200955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0130517989.USD","BK4585","EBSB","LU1699723380.USD","LU0130102774.USD","BK4196","BK4154","CNC","LU2362541513.USD","LU0130518102.USD","BK4139","LU0130103400.USD","LU1201861249.SGD","LU2362540622.SGD","LU0648001328.SGD","IE0034235188.USD","LU2065731478.USD","BK4198","OPCH","LU0477156953.USD","LU1291159041.SGD","BK4588","LU0477156797.USD","BVS","LU1989771016.USD","LU0980610538.SGD","ADMA","LU2362541273.HKD","LU0648000940.SGD","LU1201861165.SGD"],"gpt_icon":0},{"id":"2520359826","title":"Why Adma Biologics (ADMA) Outpaced the Stock Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520359826","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520359826?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:50","pubTimestamp":1742248214,"startTime":"0","endTime":"0","summary":"In the latest trading session, Adma Biologics  closed at $18.67, marking a +1.3% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Elsewhere, the Dow saw an upswing of 0.85%, while the tech-heavy Nasdaq appreciated by 0.31%.Prior to today's trading, shares of the infectious disease drug developer had gained 15.91% over the past month. This has outpaced the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69% in that time.The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is expected to report EPS of $0.16, up 100% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $119.1 million, up 45.46% from the year-ago period.It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-adma-biologics-adma-outpaced-215014073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2519386307","title":"Will ADMA Biologics Stock Continue Its Momentum in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386307","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386307?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:40","pubTimestamp":1741959600,"startTime":"0","endTime":"0","summary":"ADMA Biologics ADMA put up a phenomenal performance in 2024 and the rally continues in 2025 as well.Last week, ADMA Biologics announced results for its fourth quarter and full-year 2024 and provided a business update. While adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate by a penny, revenues of $118 million beat the consensus estimate of $112 million.Nonetheless, a single quarter’s results are not important for long-term investors. Let's analyze ADMA’s fundamentals in this scenario.The company’s top line currently comprises sales of three FDA-approved products, which are Bivigam , Asceniv  and Nabi-HB .Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.Concurrent with its fourth-quarter results, ADMA upped its financial targets. ADMA now expects to gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-stock-continue-momentum-134000162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ADMA","TAK","GRFS","BK4139"],"gpt_icon":0},{"id":"2517508314","title":"How This Top Small-Cap Growth Fund Wins Big","url":"https://stock-news.laohu8.com/highlight/detail?id=2517508314","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517508314?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:00","pubTimestamp":1741348833,"startTime":"0","endTime":"0","summary":"In a stock market that favors the giants, it's still possible to reap big gains investing in Wall Street's small fries.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2017/04/SILO-MUTUALFUNDS-042417-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/04/SILO-MUTUALFUNDS-042417-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/etfs-and-funds/mutual-funds/stock-market-how-this-top-small-cap-growth-fund-wins-big/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4139","BK4204","IE0009354923.USD","LRN","BK4150","BK4196","LU2517655374.HKD","LU2517655291.USD","LINC","LU2362541273.HKD","LU2517655028.SGD","LU0566484027.USD","LU1559883803.SGD","WGS","ADMA","LU2362540622.SGD","LU2362541513.USD","RSI"],"gpt_icon":1},{"id":"1190328774","title":"Stock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1190328774","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190328774?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 22:44","pubTimestamp":1741185860,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc.  stock surged 5.17% in Wednesday's intraday trading session, driven by positive analyst sentiment and optimism about the company's growth prospects.Mizuho Securities analyst Anthony Petrone maintained a \"Buy\" rating on ADMA stock earlier this week, citing the company's transition to a new auditor and growth opportunities. The favorable analyst coverage likely boosted investor confidence, fueling the stock's upward momentum.ADMA Biologics, a biopharmaceutical company, is focus","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ADMA Biologics Soars 5.17% on Analyst's Buy Rating and Growth Prospects","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2517095407","title":"Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2517095407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517095407?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 12:56","pubTimestamp":1741150602,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on ADMA stock, giving a Buy rating on March 3. Anthony Petrone has gi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-adma-biologics-amid-transition-to-new-auditor-and-growth-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-adma-biologics-amid-transition-to-new-auditor-and-growth-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADMA"],"gpt_icon":0},{"id":"2517936167","title":"ADMA Biologics Earnings Call Highlights Strong Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517936167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517936167?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 08:22","pubTimestamp":1741134151,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (($ADMA)) has held its Q4 earnings call. Read on for the main highlights of the call. ADMA Biologics Inc. recently held its earn...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adma-biologics-earnings-call-highlights-strong-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adma-biologics-earnings-call-highlights-strong-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADMA"],"gpt_icon":0},{"id":"1169003475","title":"Stock Track | ADMA Biologics Soars 5.12% on Booming Asceniv Sales and Robust Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1169003475","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169003475?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 04:20","pubTimestamp":1741119656,"startTime":"0","endTime":"0","summary":"ADMA Biologics  stock surged 5.12% on Tuesday, driven by stellar Q4 and full-year 2024 results that underscored the increasing demand for its flagship product Asceniv and robust growth prospects for 2025 and beyond.The company achieved a remarkable 65% year-over-year increase in total revenue to $426.5 million in 2024, fueled by soaring Asceniv sales. Gross margins expanded significantly to 51.5%, up from 34.4% in 2023, reflecting the favorable product mix and higher-margin Asceniv sales.Driven ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ADMA Biologics Soars 5.12% on Booming Asceniv Sales and Robust Growth Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2517601522","title":"Q4 2024 ADMA Biologics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2517601522","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517601522?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 00:54","pubTimestamp":1741107257,"startTime":"0","endTime":"0","summary":"Skyler Bloom; Corporate Strategy, Business Development; ADMA Biologics Inc. Adam Grossman; President, Chief Executive Officer, Co-Founder, Interim Chief Financial Officer, Director; ADMA Biologics Inc. Brad Tade; Chief Financial Officer & Treasurer; ADMA Biologics Inc. Good afternoon and welcome to the ADMA biologics 4th quarter and full year 2024 financial results and business update conference call on Monday, March 3, 2025. At this time, all participants are in the listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call. At this time, I would like to introduce the company. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-adma-biologics-inc-165417852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"2516567036","title":"ADMA Biologics Price Target Maintained With a $25.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567036","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516567036?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:53","pubTimestamp":1741099980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 09:53 ET (14:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"gpt_icon":0},{"id":"2516064324","title":"ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2516064324","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516064324?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 15:03","pubTimestamp":1741071832,"startTime":"0","endTime":"0","summary":"Total Revenue : $117.5 million, up 59% from Q4 2023.Total Revenue : $426.5 million, up 65% from FY 2023.Adjusted EBITDA : $164.6 million, up from $40.2 million in FY 2023.GAAP Net Income : $111.9 million, compared to a net loss of $17.6 million in Q4 2023.GAAP Net Income : $197.7 million, compared to a net loss of $28.2 million in FY 2023.Adjusted Net Income : $119.2 million, up from $0.7 million in FY 2023.GuruFocus has detected 1 Warning Sign with ADMA.ADMA Biologics Inc  reported a significant revenue increase of 65% year-over-year, reaching $426.5 million in 2024.ADMA Biologics Inc  raised its financial guidance, expecting total revenue to exceed $490 million in 2025 and $605 million in 2026.Q: Can you give us a sense of how many third-party supply contracts are currently up and running and the expected cadence for 2025?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-q4-070352441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"2516616286","title":"ADMA Biologics Reports Strong 2024 Financial Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2516616286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516616286?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 12:01","pubTimestamp":1741060919,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc ( ($ADMA) ) has released its Q4 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-strong-2024-financial-performance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-strong-2024-financial-performance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2516698044","title":"ADMA Biologics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516698044?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 08:24","pubTimestamp":1741047849,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc reports results for the quarter ended December 31 - Earnings SummaryADMA Biologics Inc ADMA.OQ reported quarterly adjusted earnings of 14 cents per share for the quarter ended Decem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN01J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"gpt_icon":0},{"id":"2516693547","title":"ADMA Biologics Delays 10-K Filing Amid Auditor Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693547?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 08:17","pubTimestamp":1741047447,"startTime":"0","endTime":"0","summary":"ADMA Biologics ( ($ADMA) ) has released a notification of late filing. ADMA Biologics, Inc. has announced a delay in filing its Form 10-K (Yearly R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adma-biologics-delays-10-k-filing-amid-auditor-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adma-biologics-delays-10-k-filing-amid-auditor-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2516669525","title":"ADMA Biologics Swings to Q4 Profit, Revenue Increases; Shares Rise After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2516669525","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516669525?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 05:38","pubTimestamp":1741037926,"startTime":"0","endTime":"0","summary":"ADMA Biologics  reported Q4 earnings Monday of $0.46 per diluted share, compared with a loss of $0.08 a year earlier.Three analysts polled by FactSet expected $0.15.Revenue in the three months ended Dec. 31 rose to $117.5 million from $73.9 million a year earlier.Three analysts surveyed by FactSet expected $112.8 million.The company boosted its 2025 revenue forecast to $490 million from $465 million and forecast 2026 revenue of $605 million.Three analysts polled by FactSet expect revenue of $479.2 million in 2025 and $599 million in 2026.The company's shares rose 6.2% in after-hours trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADMA"],"gpt_icon":0},{"id":"2516882664","title":"Adma Biologics: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2516882664","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516882664?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 05:29","pubTimestamp":1741037345,"startTime":"0","endTime":"0","summary":"RAMSEY, N.J.  — RAMSEY, N.J.  — Adma Biologics Inc.  on Monday reported fourth-quarter net income of $111.9 million, after reporting a loss in the same period a year earlier.The Ramsey, New Jersey-based company said it had profit of 46 cents per share. Earnings, adjusted for non-recurring gains, came to 14 cents per share.The infectious disease drug developer posted revenue of $117.5 million in the period.For the year, the company reported net income of $197.7 million, or 81 cents per share, swinging to a profit in the period. Revenue was reported as $426.5 million.Adma Biologics shares have dropped nearly 8% since the beginning of the year. In the final minutes of trading on Monday, shares hit $15.83, nearly tripling in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-q4-earnings-snapshot-212905596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0807},{"period":"1month","weight":0.2765},{"period":"3month","weight":0.1614},{"period":"6month","weight":0.0401},{"period":"1year","weight":2.1643},{"period":"ytd","weight":0.179}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.027611},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.01132},{"month":3,"riseRate":0.636364,"avgChangeRate":0.110242},{"month":4,"riseRate":0.6,"avgChangeRate":0.007327},{"month":5,"riseRate":0.7,"avgChangeRate":0.076004},{"month":6,"riseRate":0.2,"avgChangeRate":-0.053782},{"month":7,"riseRate":0.7,"avgChangeRate":0.113035},{"month":8,"riseRate":0.3,"avgChangeRate":0.011317},{"month":9,"riseRate":0.2,"avgChangeRate":-0.020319},{"month":10,"riseRate":0.4,"avgChangeRate":-0.051308},{"month":11,"riseRate":0.6,"avgChangeRate":0.079185},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.06159}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction